Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -8.62 | 2.73 | 2.93 | 2.83 |
| FCF Yield | 0.00% | 0.69% | 0.24% | 0.88% |
| EV / EBITDA | 0.00 | 124.58 | 131.47 | 132.97 |
| Quality | ||||
| ROIC | 0.00% | 1.88% | 2.09% | 1.63% |
| Gross Margin | 69.93% | 67.65% | 63.26% | 58.56% |
| Cash Conversion Ratio | 1.62 | 0.81 | 2.59 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.04% | 11.34% | 10.40% | 9.71% |
| Free Cash Flow Growth | 0.00% | 209.60% | -69.56% | 66.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 8.41 | 9.02 | 10.02 |
| Interest Coverage | 12.07 | 9.10 | 10.30 | 4.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.57 | 0.60 | 0.67 |
| Cash Conversion Cycle | 0.00 | 154.46 | 149.86 | 138.57 |